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E D I T O R I A L
Moving toward personalizing MELD exceptions in liver 
transplantation for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has become a leading indication for 
liver transplantation (LT) in the United States over the past 2 de‐
cades, accounting for nearly 25% of all LTs conducted yearly.1	Access	
to HCC‐related LT has been accomplished primarily through granting 
Model for End‐Stage Liver Disease (MELD) exception points, which 
aim to balance the risk of death and waitlist dropout with post‐LT 
HCC recurrence. Given the finite number of organs, this increase 
in HCC‐related LT has come at the expense of patients with end‐
stage liver disease. Thus, in order to better balance waitlist drop‐
out between HCC and non‐HCC listed patients, MELD exception 
policies have undergone several changes since instituted in 2002.2 
Nevertheless, inequities exist in waitlist mortality and survival ben‐
efit from LT between HCC and non‐HCC candidates.3 Furthermore, 
all eligible HCC patients meeting Milan criteria (1 HCC less than 
5 cm or up to 3 HCCs, each less than 3 cm) receive the same MELD 
exception prioritization, despite having variable rates of tumor pro‐
gression, waitlist dropout, and post‐LT recurrence based on their in‐
dividual tumor biology. In the face of this inadequate one‐size‐fits‐all 
paradigm, continual efforts are necessary to optimize prioritization 
for HCC patients.
To define characteristics of HCC‐exception eligible patients 
that portend a low risk of waitlist dropout, Mehta et al4 retrospec‐
tively analyzed the United Network for Organ Sharing (UNOS) da‐
tabase from 2011 to 2014. The authors restricted their analysis 
to regions with protracted average wait times for LT, and identi‐
fied 4 independent predictors associated with low risk of waitlist 
dropout	 including	Child	Pugh	A	cirrhosis,	MELD	score	<15,	alpha	
fetoprotein	<20,	and	a	unifocal	HCC	2‐3	cm	in	maximum	diameter.	
Patients meeting all 4 criteria comprised 11.9% of all HCC patients 
with MELD exceptions and had a lower risk of waitlist dropout 
(5.5% vs 20.0%; P	<	 .001)	and	a	higher	intention	to	treat	survival	
(94.0% vs 78.5%; P	<	 .001)	when	compared	to	all	other	HCC	pa‐
tients at 1 year from listing. These criteria maintained good per‐
formance characteristics (c‐statistic = 0.69) in a national validation 
cohort from 2015 to 2016, which included the period after the 
institution of the most recent MELD‐exception policies requiring 
a 6‐month waiting period prior to the granting of exception points. 
The authors conclude that patients with this lowest risk of dropout 
should receive less priority for LT than average‐risk patients. This 
is compatible with a recent policy proposal from UNOS to exclude 
patients with a unifocal 2‐3 cm HCC who demonstrate a complete 
radiographic response to locoregional therapy from attaining a 
MELD exception.5	Although	the	policy	was	not	ultimately	adopted,	
the results of the analysis from Mehta et al suggest that it should 
be revisited.
There are, however, notable limitations to this analysis that should 
temper the conclusions from the authors. First, the UNOS database 
lacks important granularity, particularly dynamic changes on the wait‐
list and missing data on locoregional therapies. These deficiencies 
resulted in the proposal of a static model based solely on listing char‐
acteristics,	which	can	be	problematic.	A	“low‐risk”	patient	with	a	single	
tumor, compensated liver disease, and low alpha fetoprotein at listing 
may develop declining liver function, new tumors, and rising alpha fe‐
toprotein, which would limit application of locoregional therapy and/or 
alter their risk profile. Similarly, postlocoregional therapy decompensa‐
tion may change the waitlist dropout in otherwise low‐risk candidates. 
In these and other circumstances, a safety net framework would be 
necessary to salvage these patients. Second, the analyses included a 
large proportion of patients who did not receive locoregional therapy 
prior to LT. With utilization of pre‐LT locoregional therapy now a uni‐
versal practice in the era of a 6‐month mandatory wait time HCC ex‐
ception policy, and with forthcoming changes in the regional median 
MELD at transplantation, the result of this study may not apply entirely 
to contemporary HCC patient populations. Finally, deprioritizing these 
lowest	 risk	HCC	patients	may	 lead	 to	an	 “enrichment”	of	higher	 risk	
candidates, with the unintended effect of increasing the rate of post‐LT 
HCC	recurrence	and	consequently	the	risk	of	short‐term	mortality.	A	
dynamic model simultaneously evaluating the evolution of both liver 
function and tumor burden over the waitlist period, although more 
complex, may ultimately be necessary to truly maximize the transplant 
benefit of scarce donor organs.
In summary, Mehta et al make a compelling argument that low‐
risk patients with HCC should have a for lower priority for HCC 
exception, which is a welcomed step to differentially prioritize HCC 
candidates based on individualized factors. Implementation of such 
a policy requires further data and modeling of its impact on waitlist 
mortality and access to LT. Ultimately, validation of better biomark‐
ers of tumor biology through either direct sampling or noninvasive 
means	 (ie,	 circulating	 tumor	 cells,	 DNA	methylation	 patterns,	 ra‐
diomics, and so on) may better guide transplant priority decision‐
making. While these technologies are being developed and refined, 
defining and deprioritizing low‐risk HCC patients is a practical ap‐
proach toward harmonizing benefits and risks for all patients on the 
LT waitlist.
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